Avalyn Pharma (AVLN) Q1 2026 earnings summary

Executive summary

• Completed IPO in May 2026, raising $345.0 million in gross proceeds ($316.1 million net), with all preferred stock converted to common stock.

• Focused on developing inhaled therapies for rare respiratory diseases, with lead candidates AP01 and AP02 in Phase 2/2b trials and AP03 in preclinical development.

• No revenue generated; accumulated deficit reached $292.2 million as of March 31, 2026.

• Strengthened leadership team with new appointments in legal and commercial roles.

Financial highlights

• Net loss for Q1 2026 was $26.9 million, up from $17.5 million in Q1 2025, driven by increased R&D and G&A expenses.

• Operating expenses rose to $27.9 million from $18.7 million year-over-year.

• R&D expenses increased to $22.9 million from $15.3 million; G&A expenses rose to $5.0 million from $3.4 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $123.1 million at quarter-end, excluding IPO proceeds.

• Net cash used in operating activities was $29.8 million for Q1 2026.

Outlook and guidance

• Cash runway, including IPO proceeds, projected to fund operations into 2029, but substantial additional funding will be needed for future development and commercialization.

• Expenses and operating losses anticipated to increase as clinical programs advance.

• MIST Phase 2b trial of AP01 in PPF to complete enrollment mid-2026, with topline data expected in H2 2027.

• AURA Phase 2 trial of AP02 in IPF enrolling, with topline data anticipated by end of 2027.

• Phase 1 trial of AP03 planned to initiate by end of 2026.